LT3448849T - Indazolo sintezė - Google Patents

Indazolo sintezė

Info

Publication number: LT3448849T
Authority: LT; Lithuania
Prior art keywords: indazole; synthesis
Prior art date: 2016-04-29

Application number

LTEP17719256.4T

Other languages

English (en)

Inventor

Tobias THALER

Johannes Platzek

Nicolas GUIMOND

Original Assignee

Bayer Pharma Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-29

Filing date

2017-04-25

Publication date

2020-09-25

2017-04-25 Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft

2020-09-25 Publication of LT3448849T publication Critical patent/LT3448849T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

LTEP17719256.4T 2016-04-29 2017-04-25 Indazolo sintezė LT3448849T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP16167649		2016-04-29
EP16167650		2016-04-29
PCT/EP2017/059748 WO2017186693A1 (en)	2016-04-29	2017-04-25	Synthesis of indazoles

Publications (1)

Publication Number	Publication Date
LT3448849T true LT3448849T (lt)	2020-09-25

Family

ID=58579196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP17719256.4T LT3448849T (lt)	2016-04-29	2017-04-25	Indazolo sintezė

Country Status (38)

Country	Link
US (2)	US10501437B2 (lt)
EP (2)	EP3448849B1 (lt)
JP (2)	JP6916207B2 (lt)
KR (2)	KR102409105B1 (lt)
CN (4)	CN118184628A (lt)
AU (2)	AU2017256659B2 (lt)
BR (1)	BR112018072247A2 (lt)
CA (1)	CA3022327C (lt)
CL (2)	CL2018003097A1 (lt)
CO (2)	CO2018011655A2 (lt)
CU (1)	CU24593B1 (lt)
DK (1)	DK3448849T3 (lt)
DO (1)	DOP2018000236A (lt)
EA (1)	EA038103B1 (lt)
EC (1)	ECSP18081451A (lt)
ES (1)	ES2801800T3 (lt)
GE (1)	GEP20217230B (lt)
HU (1)	HUE049331T2 (lt)
IL (2)	IL262391B (lt)
JO (2)	JOP20170102B1 (lt)
LT (1)	LT3448849T (lt)
MA (1)	MA44758A (lt)
MX (2)	MX385470B (lt)
NI (1)	NI201800111A (lt)
NZ (1)	NZ746868A (lt)
PE (2)	PE20240651A1 (lt)
PH (1)	PH12018502288B1 (lt)
PL (1)	PL3448849T3 (lt)
PT (1)	PT3448849T (lt)
RS (1)	RS60419B1 (lt)
SG (2)	SG11201809172WA (lt)
SI (1)	SI3448849T1 (lt)
SV (1)	SV2018005776A (lt)
TN (1)	TN2018000359A1 (lt)
TW (3)	TWI671291B (lt)
UA (2)	UA123550C2 (lt)
UY (2)	UY37217A (lt)
WO (2)	WO2017186700A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3705B1 (ar)	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3423446B1 (de)	2016-03-03	2020-09-16	Bayer Pharma Aktiengesellschaft	Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
KR102409105B1 (ko)	2016-04-29	2022-06-16	바이엘 파마 악티엔게젤샤프트	인다졸의 합성
UA123169C2 (uk)	2016-04-29	2021-02-24	Байєр Фарма Акцієнгезелльшафт	Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду
SG10202011653WA (en) *	2016-06-01	2020-12-30	Bayer Pharma AG	Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
MY199070A (en)	2016-06-01	2023-10-12	Bayer Pharma AG	Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals
CN112243438B (zh)	2018-06-25	2022-03-15	正大天晴药业集团股份有限公司	作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物
KR102392788B1 (ko)	2019-01-08	2022-04-28	주식회사 엘지에너지솔루션	폴더블 사이드 플레이트를 구비하는 배터리 모듈 및 그 제조 방법
CN111499612B (zh) *	2019-01-30	2022-12-30	上海美悦生物科技发展有限公司	一种作为irak抑制剂的化合物及其制备方法和用途
CN113521079A (zh) *	2020-04-20	2021-10-22	上海领泰生物医药科技有限公司	Irak4抑制剂在治疗ali/ards中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7163937B2 (en)	2003-08-21	2007-01-16	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
US20100048660A1 (en)	2006-02-10	2010-02-25	Graham Michael Wynne	Treatment of duchenne muscular dystrophy
US7879887B2 (en)	2006-06-29	2011-02-01	Nissan Chemical Industries, Ltd.	α-amino acid derivatives and medicaments containing the same as an active ingredient
KR20090049076A (ko)	2006-09-07	2009-05-15	바이오겐 아이덱 엠에이 인코포레이티드	인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체
WO2011043479A1 (ja)	2009-10-09	2011-04-14	田辺三菱製薬株式会社	脳梗塞治療薬
WO2011153588A1 (en)	2010-06-10	2011-12-15	Biota Scientific Management Pty Ltd	Viral polymerase inhibitors
BR112013015460B1 (pt)	2010-12-20	2022-01-25	Merck Serono S.A.	Derivados de indazolil triazol, kit, e composição farmacêutica
WO2013106254A1 (en)	2012-01-11	2013-07-18	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
JP6283862B2 (ja) *	2012-12-07	2018-02-28	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規インダニルオキシジヒドロベンゾフラニル酢酸
US9126984B2 (en) *	2013-11-08	2015-09-08	Iteos Therapeutics	4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh)	2013-12-19	2019-08-01	德商拜耳製藥公司	新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
SG11201605408RA (en)	2014-01-10	2016-07-28	Aurigene Discovery Tech Ltd	Indazole compounds as irak4 inhibitors
JO3705B1 (ar)	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
UY36660A (es)	2015-04-30	2016-11-30	Bayer Pharma AG	Combinaciones de inhibidores de irak4
BR112018000624A2 (pt)	2015-07-15	2018-09-18	Aurigene Discovery Technologies Limited	compostos de indazol e azaindazol como inibidores de irak-4
EP3423446B1 (de)	2016-03-03	2020-09-16	Bayer Pharma Aktiengesellschaft	Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
EP3219329A1 (en) *	2016-03-17	2017-09-20	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib
KR102409105B1 (ko)	2016-04-29	2022-06-16	바이엘 파마 악티엔게젤샤프트	인다졸의 합성
UA123169C2 (uk)	2016-04-29	2021-02-24	Байєр Фарма Акцієнгезелльшафт	Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду
SG10202011653WA (en)	2016-06-01	2020-12-30	Bayer Pharma AG	Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
MY199070A (en)	2016-06-01	2023-10-12	Bayer Pharma AG	Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals

2017
- 2017-04-25 KR KR1020187030702A patent/KR102409105B1/ko not_active Expired - Fee Related
- 2017-04-25 CU CU2018000130A patent/CU24593B1/es unknown
- 2017-04-25 CN CN202410286070.1A patent/CN118184628A/zh active Pending
- 2017-04-25 US US16/097,506 patent/US10501437B2/en active Active
- 2017-04-25 PL PL17719256T patent/PL3448849T3/pl unknown
- 2017-04-25 EA EA201892407A patent/EA038103B1/ru unknown
- 2017-04-25 MX MX2018013227A patent/MX385470B/es unknown
- 2017-04-25 GE GEAP201714932A patent/GEP20217230B/en unknown
- 2017-04-25 RS RS20200749A patent/RS60419B1/sr unknown
- 2017-04-25 SG SG11201809172WA patent/SG11201809172WA/en unknown
- 2017-04-25 CA CA3022327A patent/CA3022327C/en active Active
- 2017-04-25 PE PE2023003161A patent/PE20240651A1/es unknown
- 2017-04-25 MA MA044758A patent/MA44758A/fr unknown
- 2017-04-25 JP JP2018556406A patent/JP6916207B2/ja not_active Expired - Fee Related
- 2017-04-25 WO PCT/EP2017/059764 patent/WO2017186700A1/en not_active Ceased
- 2017-04-25 DK DK17719256.4T patent/DK3448849T3/da active
- 2017-04-25 CN CN201780026606.4A patent/CN109071491B/zh not_active Expired - Fee Related
- 2017-04-25 CN CN202110078561.3A patent/CN112898269A/zh active Pending
- 2017-04-25 BR BR112018072247-2A patent/BR112018072247A2/pt not_active Application Discontinuation
- 2017-04-25 US US16/097,463 patent/US10633365B2/en active Active
- 2017-04-25 EP EP17719256.4A patent/EP3448849B1/en active Active
- 2017-04-25 WO PCT/EP2017/059748 patent/WO2017186693A1/en not_active Ceased
- 2017-04-25 SI SI201730292T patent/SI3448849T1/sl unknown
- 2017-04-25 PE PE2018002240A patent/PE20190172A1/es unknown
- 2017-04-25 EP EP17718559.2A patent/EP3448847A1/en not_active Withdrawn
- 2017-04-25 LT LTEP17719256.4T patent/LT3448849T/lt unknown
- 2017-04-25 KR KR1020187030703A patent/KR102379948B1/ko not_active Expired - Fee Related
- 2017-04-25 SG SG11201808686VA patent/SG11201808686VA/en unknown
- 2017-04-25 AU AU2017256659A patent/AU2017256659B2/en not_active Ceased
- 2017-04-25 ES ES17719256T patent/ES2801800T3/es active Active
- 2017-04-25 PT PT177192564T patent/PT3448849T/pt unknown
- 2017-04-25 TN TNP/2018/000359A patent/TN2018000359A1/en unknown
- 2017-04-25 CN CN201780040907.2A patent/CN109415339A/zh active Pending
- 2017-04-25 NZ NZ746868A patent/NZ746868A/en unknown
- 2017-04-25 AU AU2017257208A patent/AU2017257208B2/en not_active Ceased
- 2017-04-25 UA UAA201811327A patent/UA123550C2/uk unknown
- 2017-04-25 JP JP2018556410A patent/JP6821701B2/ja active Active
- 2017-04-25 MX MX2018013232A patent/MX380550B/es unknown
- 2017-04-25 UA UAA201811328A patent/UA122882C2/uk unknown
- 2017-04-25 HU HUE17719256A patent/HUE049331T2/hu unknown
- 2017-04-27 JO JOP/2017/0102A patent/JOP20170102B1/ar active
- 2017-04-27 JO JOP/2017/0101A patent/JOP20170101B1/ar active
- 2017-04-28 TW TW106114179A patent/TWI671291B/zh active
- 2017-04-28 TW TW108120349A patent/TW201936599A/zh unknown
- 2017-04-28 TW TW106114181A patent/TWI651316B/zh not_active IP Right Cessation
- 2017-04-28 UY UY0001037217A patent/UY37217A/es active IP Right Grant
- 2017-04-28 UY UY0001037214A patent/UY37214A/es not_active Application Discontinuation
- 2017-05-25 PH PH1/2018/502288A patent/PH12018502288B1/en unknown
2018
- 2018-10-15 IL IL262391A patent/IL262391B/en unknown
- 2018-10-16 IL IL262413A patent/IL262413B/en active IP Right Grant
- 2018-10-29 CL CL2018003097A patent/CL2018003097A1/es unknown
- 2018-10-29 CL CL2018003085A patent/CL2018003085A1/es unknown
- 2018-10-29 DO DO2018000236A patent/DOP2018000236A/es unknown
- 2018-10-29 SV SV2018005776A patent/SV2018005776A/es unknown
- 2018-10-29 CO CONC2018/0011655A patent/CO2018011655A2/es unknown
- 2018-10-29 CO CONC2018/0011607A patent/CO2018011607A2/es unknown
- 2018-10-29 EC ECSENADI201881451A patent/ECSP18081451A/es unknown
- 2018-10-29 NI NI201800111A patent/NI201800111A/es unknown

Also Published As

Publication number	Publication date
US10501437B2 (en)	2019-12-10
DOP2018000236A (es)	2019-01-15
WO2017186693A1 (en)	2017-11-02
EA201892407A1 (ru)	2019-05-31
CN109071491A (zh)	2018-12-21
EP3448847A1 (en)	2019-03-06
MA44758A (fr)	2019-03-06
JP2019514921A (ja)	2019-06-06
PE20240651A1 (es)	2024-04-04
AU2017256659A1 (en)	2018-10-25
BR112018072213A2 (pt)	2019-02-12
DK3448849T3 (da)	2020-06-29
SI3448849T1 (sl)	2020-07-31
US20190152944A1 (en)	2019-05-23
MX2018013232A (es)	2019-02-13
CN118184628A (zh)	2024-06-14
CN109415339A (zh)	2019-03-01
UA123550C2 (uk)	2021-04-21
BR112018072247A2 (pt)	2019-02-12
IL262413A (en)	2018-12-31
ECSP18081451A (es)	2018-11-30
PT3448849T (pt)	2020-06-30
CN112898269A (zh)	2021-06-04
KR20180137498A (ko)	2018-12-27
CA3022329A1 (en)	2017-11-02
ES2801800T3 (es)	2021-01-13
MX385470B (es)	2025-03-18
SG11201808686VA (en)	2018-11-29
KR102409105B1 (ko)	2022-06-16
CU24593B1 (es)	2022-05-11
EA038103B1 (ru)	2021-07-06
PH12018502288A1 (en)	2019-07-15
TWI651316B (zh)	2019-02-21
EP3448849B1 (en)	2020-05-13
GEP20217230B (en)	2021-03-10
NZ746868A (en)	2025-05-30
CO2018011607A2 (es)	2018-11-22
SG11201809172WA (en)	2018-11-29
TWI671291B (zh)	2019-09-11
MX2018013227A (es)	2019-02-13
PL3448849T3 (pl)	2020-12-14
JOP20170101B1 (ar)	2022-03-14
US20190144420A1 (en)	2019-05-16
JOP20170102B1 (ar)	2023-09-17
CU20180130A7 (es)	2019-06-04
CL2018003085A1 (es)	2019-02-15
AU2017257208A1 (en)	2018-11-01
AU2017256659B2 (en)	2021-05-27
MX380550B (es)	2025-03-12
TW201738231A (zh)	2017-11-01
CL2018003097A1 (es)	2019-02-15
KR102379948B1 (ko)	2022-03-31
CA3022327A1 (en)	2017-11-02
JP6821701B2 (ja)	2021-01-27
IL262391B (en)	2022-03-01
TW201936599A (zh)	2019-09-16
JP2019514924A (ja)	2019-06-06
KR20190002468A (ko)	2019-01-08
UY37217A (es)	2017-11-30
JP6916207B2 (ja)	2021-08-11
PH12018502288B1 (en)	2022-06-10
TN2018000359A1 (en)	2020-06-15
HUE049331T2 (hu)	2020-09-28
IL262413B (en)	2021-05-31
CN109071491B (zh)	2020-08-21
EP3448849A1 (en)	2019-03-06
NI201800111A (es)	2019-08-29
TW201738233A (zh)	2017-11-01
AU2017257208B2 (en)	2022-01-20
US10633365B2 (en)	2020-04-28
PE20190172A1 (es)	2019-02-01
RS60419B1 (sr)	2020-07-31
WO2017186700A1 (en)	2017-11-02
SV2018005776A (es)	2019-03-18
UY37214A (es)	2017-11-30
CO2018011655A2 (es)	2018-11-13
UA122882C2 (uk)	2021-01-13
IL262391A (en)	2018-12-31
CA3022327C (en)	2025-05-06

Publication	Publication Date	Title
IL263586B (en)	2021-06-30	Inhibitors of the menin-mll interaction
LT3448846T (lt)	2021-07-26	Indazolų sintezė
HUE055242T2 (hu)	2021-11-29	Omecamtiv mecarbil szintézise
EP3558863A4 (en)	2020-12-16	RELATED STRUCTURES
LT3474669T (lt)	2022-06-10	Barkodu pažymėtų kombinatorinių bibliotekų generavimo būdai
HRP20251596T1 (hr)	2026-01-30	Nove upotrebe derivata piperidinil-indola
EP3402517A4 (en)	2020-01-15	Immunologic treatment of cancer
LT3137169T (lt)	2022-04-11	Lizinui specifinės demetilazės-1 inhibitoriai
LT3448849T (lt)	2020-09-25	Indazolo sintezė
HUE050564T2 (hu)	2020-12-28	Lizinspecifikus demetiláz-1 inhibitorai
LT3511319T (lt)	2023-08-25	Lizinui specifinės demetilazės-1 inhibitoriai
IL272851A (en)	2020-04-30	Methods of using dipivefrin
PL3457851T3 (pl)	2022-03-14	Pochodne sobetiromu
HRP20181441T1 (hr)	2018-11-02	Inhibitori sintaze aldosterona
EP3277701A4 (en)	2019-03-06	SYNTHESIS OF DESOSAMINES
IL254502B (en)	2020-09-30	Solid forms of menaquinols
EP3470119A4 (en)	2020-01-29	EXTINGUISHERS
DK3190088T3 (da)	2019-09-02	Fremgangsmåde til syntese af ammoniak
EP3532210A4 (en)	2020-07-01	ACOUSTIC TRANSDUCER
DK3752507T3 (da)	2023-01-09	Triazoloquinazolinon-syntese
PL3350308T3 (pl)	2021-08-23	Zastosowanie włókna liocelowego
DK3344628T3 (da)	2020-08-03	Terapeutiske forbindelser og syntese
IT201700010606A1 (it)	2018-08-13	GenialCombi di Moscarelli
IT201700068126A1 (it)	2018-12-20	Struttura di filtropressa
IT201600129753A1 (it)	2018-06-22	Struttura di calcio-balilla